Kraig Biocraft Laboratories, Inc. (KBLB)
Stock Price:
$0.140 USD
-0.007 (-4.76%)
Updated Aug 3, 2020 5:19 PM EDT - End of day
Key Info
| Market Cap |
119.62M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
844.47M |
| EPS (ttm) |
-0.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$0.140 |
| Previous Close |
$0.147 |
| Change ($) |
-0.007 |
| Change (%) |
-4.76% |
| Day's Open |
0.149 |
| Day's Range |
0.136 - 0.150 |
| Day's Volume |
744,848 |
| 52-Week Range |
0.090 - 0.335 |
More Stats
| Market Cap |
119.62M |
| Enterprise Value |
n/a |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
844.47M |
| Float |
660.14M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.01 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
0.48 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
n/a |
| Net Cash / Share |
0.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-356.41% |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Overview
No financial data available for this stock yet.
Company Details
| Full Name |
Kraig Biocraft Laboratories, Inc. |
| Country |
United States |
| Employees |
14 |
| CEO |
Kim K. Thompson |
Stock Information
| Ticker Symbol |
KBLB |
| Stock Exchange |
US OTC |
| Sector |
Basic Materials |
| Industry |
Specialty Chemicals |
| Unique Identifier |
OTCMKTS: KBLB |
Description
Kraig Biocraft Laboratories, Inc. focuses on developing protein based fibers using recombinant DNA technology for commercial applications in the United States. It develops fibers using genetic engineering technologies for use in various target markets, including textile, specialty fiber, and technical textile industries. The company was founded in 2006 and is based in Ann Arbor, Michigan.